other lymphoma subtypes. The most common gene ontology identified within the list of 88 overlapping genes is the chromatin modification and transcription gene ontology with 13 genes, for example, CREBBP, MLL2, MLL3, BCL6, HIST1H1E and EP300. Mutations of histone-modifying genes are also common in DLBCL and FL. The common origin of HRS cells and the tumor cells of DLBCL and FL is consistent with the marked overlap in the mutational spectrum. For BL, the overlap is limited and further genomic studies are awaited to clearly establish the extent of overlap. Despite the significant overlap, the majority of the genes that were mutated in HL remain unique. This indicates that the genetic events occurring during the malignant transformation in HL are distinct from those in other GC B-cellderived NHL.
of ECOG status and patient age. Taken together, the association of Bim and Hrk with CLL patient response is consistent with Bcl-x L dependence as a driver of alvocidib efficacy. Concurrently, Bad's association with TLS, which is indicative of Bcl-2's dependency, may help identify patients at risk for treatment-related toxicity. Alvocidib has demonstrated single-agent activity in relapsed/ refractory CLL patients in Phase I and Phase II clinical studies although the activity was originally limited, presumably due to high protein binding in plasma attenuating the levels of available drug in patients. 1, 2 However, Byrd and colleagues [3] [4] [5] [6] recently identified a hybrid intravenous dosing schedule that utilizes a 30-min loading dose (30 mg/m 2 ) followed by a 4-h infusion (50 mg/m 2 ). This novel dosing schedule has allowed for improved single-agent activity in relapsed and refractory CLL patients in multiple clinical studies, with overall response rates between 30 and 53%, including favorable responses in high-risk patients with 17p13.1 deletions. [3] [4] [5] [6] Response rate limitations have been compounded by treatment-related toxicities including TLS. Patient enrichment strategies that include molecular and cytogenetic approaches may enhance development of alvocidib in CLL by targeting the drug to patients who are most likely to exhibit response and least likely to experience adverse events.
Assessment of intrinsic mitochondrial apoptosis pathways by functional profiling has recently shown encouraging results for patient stratification strategies in treatment of hematologic malignancies. 7, 8 This profiling of Bcl-2 family members serves to elucidate the extent to which pro-apoptotic sensitizers (that is, Puma, Noxa, Bad, Hrk) and activators (that is, Bim) may regulate the activity of antiapoptotic proteins (that is, Mcl-1, Bcl-2, Bcl-x L ). Indeed, previous investigations have established that alvocidib potentiates pan-BH3 mimetic activity through upregulation of BH3-only proteins with coordinate downregulation of their antiapoptotic counterparts. 9 Previous studies assessing alvocidib efficacy in CLL patients ex vivo and expression levels of Bcl-2 family proteins, including Mcl-1, were not able to establish correlation with clinical efficacy. 10 Based on these observations, we have investigated the functional context of intrinsic apoptosis BH3-only proteins by mitochondrial priming assessment as a surrogate for cellular response to pro-apoptotic cues to provide a predictive strategy for CLL patient management. 7, 11 Patients were randomly segregated into two cohorts that would serve as proof-of-principle (n = 30) and validation sets (n = 32); cohorts were established merely on the basis of specimen tissue bank. (Patient information is provided in Supplementary Table 1.) Percent priming (that is, quantifiable propensity of a given BH3 peptide to induce mitochondrial depolarization relative to an uncoupling control agent) for each peptide is summarized in Supplementary Table 2 for patients who exhibited partial response (PR), stable disease (SD), or progressive disease (PD). In the training set, only Bim(0.1) and Hrk elicited significance (P = 0.014 and P = 0.0098, respectively) between biomarker and PR, SD and PD patients (regression analyses). These two markers validated (Bim P = 0.0051; Hrk P = 0.015) in the second set. When the two sets were combined (n = 62), regression indicated that Bim(0.1) and Hrk were both significant (Bim(0.1) P = 0.0027 and Hrk P = 0.00046, respectively; P-value significance at o 0.01 for Bonferroni correction as described in Methods) (Figure 1a ). Although not considered in the core group of patients initially identified and examined in this study, a subset of patients from OSU trial 0491 for which there were sufficient available vials was considered as a secondary validation set. Here, Hrk priming in PD/ SD patients displayed a mean of 6.4%, and PR patients a mean of 22.2% (n = 13; 4 PD/SD, 9 PR). Although not statistically powered, the trend towards Hrk priming correlation with clinical response was consistent (Supplementary Figure 2) . Trisomy 12 is a frequent event in CLL, occurring in~20% of patients 12 generally carrying an intermediate prognosis. 12, 13 The frequency of trisomy 12-positive patients in the EFC6663 study is in line with this (8 of 62 (13%)). Although small in number, all eight of the patients on study experienced clinical benefit (7 PR, 1 SD); whether this extends to a larger patient population needs to be explored. Approximately 35-50% of trisomy 12-positive patients also have a mutation in NOTCH1, 14 conferring adverse outcomes in some series. 15 This patient stratification strategy could benefit from layering of BH3 profiling to stratify patients who are most likely to benefit from alvocidib in future studies.
BH3 profiling biomarkers were analyzed relative to progressionfree survival (PFS) and overall survival (OS); no significant association between biomarker and outcome was observed (Supplementary Figure 3) although there was a trend between Bim(0.1) and OS (P = 0.03), and between Hrk and PFS (P = 0.08), suggesting that an appropriately powered study may demonstrate more significant correlation between these parameters.
As TLS remains a concern in patients prescribed certain therapies, including alvocidib, we sought to determine if BH3 profiling could be used to identify patients at risk for experiencing toxicity. Supplementary Table 3 summarizes the association of BH3 profiling biomarkers with TLS status for 48 patients for whom toxicity data were available. Here, both higher Bad and Puma(10) priming scores were significantly associated with TLS ( Figure 2a ) by Wilcoxon (P = 0.0083 and P = 0.0080, respectively) and logistic regression (P = 0.012 and P = 0.012, respectively). None of the other BH3 profiling biomarkers was significant (P40.05). The AUC statistic indicated that each marker held a significant ability to predict TLS status; Puma(10) AUC = 0.75 (P = 0.00079) and Bad AUC = 0.75 (P = 0.00072). Puma (10) and Bad when added together did not improve the predictive capacity of either marker independently.
Patient age (P = 0.034, Wilcoxon; P = 0.067, logistic regression) and baseline ECOG status (P = 0.021, Wilcoxon; P = 0.031, logistic regression) showed significant association or borderline association with toxicity (Supplementary Table 3 ). Multivariate analyses, with inclusion of both patient age and ECOG status to Bad BH3 profiling, resulted in increase in AUC from 0.75 to 0.85, and improved P (from 0.0007 to o 0.0001) (Figure 2b) .
Mitochondrial priming readout values from Hrk and Bim(0.1), both with a capacity to bind to and modulate the activity of antiapoptotic Bcl-x L , are the markers statistically associated with response, indicating this clinical end point is driven by Bcl-x L dependency. Patients likely to exhibit TLS are predicted by Bad priming; the indicative toxicity may be driven by its antiapoptotic binding partner Bcl-2. One plausible mechanism to explain the observed phenomenon is that clinical response and TLS are occurring via the action of alvocidib on two clonally related but biologically distinct cell subpopulations, one driven by Bcl-x L and the other by Bcl-2. Interestingly, both subpopulations would by definition comprise B-cell populations as the BH3 profiling assay here is performed on a patient specimen after purification and elimination of non-B-cells. Additional work will be required to further characterize the presence and composition of these distinct subpopulations. Priming by Noxa, a specific proapoptotic modulator of antiapoptotic Mcl-1, is not associated with either alvocidib response or TLS, consistent with Mcl-1 not being a driver mechanism.
Conceivably, patients could be stratified by cytogenetics and BH3 profiling to increase the overall response rate from 35 to 50% as observed in previous clinical studies. In the current patient set, 23 of the 62 analyzed patients achieved a PR to alvocidib (37.1%.) In our analyses, the combination of Hrk and trisomy 12 yielded an AUC of 0.83. By closer examination of the ROC curves, 95.6% of responder patients were identified (sensitivity) concurrently to discrimination of 66.7% of likely PD/SD patients (specificity). If the predictive value of such an applied biomarker is to triage the likely non-responder patients (here the triaging of 26 PD/SD patients, while also mis-identifying 1 likely PR patient), then the response rate increases from 37.1 to 62.9% (an overall 69.5% improvement of response rate). Similarly, TLS incidence could be decreased from 13% observed in the EFC6663 study to a minimal number moving forward. While larger cohorts will be required to fully define the extent of medical utility for such diagnostics, these early observations may hold promise for alvocidib impact in CLL patient options and improved outcomes.
